Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
Closed (no longer recruiting)Last updated: 9 January 2024
Clinical summaryEligibilityParticipating hospitalsSupport
Clinical summary
Summary
Eligible patients will be randomised to receive either a 400mg Pyrotinib maleate tablet once daily on a continuous dosing schedule over a 21-day cycle, OR a 75mg/m2 docetaxel injection once every three-weeks.
Conditions
This trial is treating patients with non-small cell lung cancer.
Cancer
Lung cancer
Age
18+
Phase
III
Trial Acronym
PYRAMID-1
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT04447118
- HR-BLTN-III-NSCLC
Trial sponsor
Jiangsu HengRui Medicine Co., Ltd.
Scientific Title
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Share with email
Print this page
Download brochure
Eligibility
Inclusion
- Signed and dated written informed consent which is approved by IRB/EC, willing and able to comply with scheduled treatment, all examinations at study visits, and other study procedures.
- ECOG PS 0-1.
- Have histologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC disease.
- Before enrollment, a documented confirmed presence of activating mutations in exon 20 of the HER2 gene must be provided. Sufficient tumor tissue samples should be provided to retrospectively confirm the mutation status of the HER2 gene.
- Must have measureable disease per RECIST v1.1.
- For advanced NSCLC, patients must have had progressive disease on or after a platinum based chemotherapy, with or without immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) and/or anti-angiogenic drugs. No more than 2 prior lines of systemic therapy are allowed.
- The laboratory test values must meet the following standards to manifest that the functional level of important organs/systems meets the requirements.
- Female patient of childbearing potential (WOCBP) and male patient whose - partner is WOCBP must agree to use effective contraception method during the study period.
Exclusion
- Malignant tumors with other pathological types.
- Medical history of other active malignancies within last 5 years.
- Subjects with active CNS metastases.
- Previously treated with targeted drugs for HER2 gene mutations,or previously treated with docetaxel.
- Prior to the first dose of study treatment, patients with severe effusions with clinical symptoms, severe cardiac disease, or severe infection.
- Prior to the first dose of study treatment, patients with diseases or special conditions that affect drug administration and absorption.
- Congenital or acquired immunodeficiency.
- History of allergy to the study drugs or components.
- Prior to the first dose of study treatment, or during the study period, patients receive or are anticipated to receive continuous strong CYP3A4 inducers or inhibitors, P-gp inhibitors, or medications that are known to cause QT/QTc prolongation.
Inclusion
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
Participating hospitals
+ Show non-recruiting hospitals
Closed hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Get Support
Cancer Connect
Speak with someone who has cancer clinical trial experience.
Learn more
Cancer Council’s cancer nurses
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Learn more
Information for family, friends and carers
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Learn more
Report inaccuracy
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.
Submitting ... Please wait
";}});$(this).html(itemList);});//Sort Hospital Alphabetically$("#TrialDetails-Hospitals .sites").each(function(){var sortHospitals = $(this).children(".site").sort(function(a, b) {return String.prototype.localeCompare.call($(a).data('site').toLowerCase(), $(b).data('site').toLowerCase());});$(this).empty().append(sortHospitals);});//Download Resources$("#Trials-Tools-Booklet").css("display","none");if (valueExists($("#Trials-CancerStream").html())) {$.ajax({type: "GET", url: "/downloads/feeds/keywords.json?version=20240429",async: false,success: function(response){var itemArray = ($("#Trials-CancerStream").html() + ",").split(",");$.each(response, function (key, val) {if(valueExists(val.cancertype.trim())){$.each(itemArray, function(cncrKey,cncrValue) { if(valueExists(cncrValue) && (cncrValue == val.cancertype.trim()) && valueExists(val.resourcelink)) { $("#Trials-Tools-Booklet").css("display","inline-block");$("#Trials-Tools-Booklet a").attr("href",val.resourcelink);return false;}});}});}});}//Conflicting Inclusion statement - Append ORif($("#TrialDetails-Eligibility .cols-2 .col.first ul").length > 0){var conflictFound = false;$('#TrialDetails-Eligibility .cols-2 .col.first ul li').each(function(index, item) {if($(this).html() == "Your cancer has not spread to other parts of the body."){conflictFound = true;}else if(conflictFound && ($(this).html() == "Your cancer has spread to other parts of the body.")){$("#TrialDetails-Eligibility .cols-2 .col.first ul li:eq(" + (index-1) + ")").append("
");}});}});//Sticky tab menu$(window).scroll(function(){pageOffsetTop = $(this).scrollTop();if(pageOffsetTop >= headerOffset) { $("#TrialDetails-Tabs").addClass("sticky"); } else {$("#TrialDetails-Tabs").removeClass("sticky"); }});//Print pagefunction printThisPage(){window.print();}//Feedback Form Validationfunction ValidateTrialFeedbackForm() {var validForm = true, emailFormat = /^\w+([\.-]?\w+)*@\w+([\.-]?\w+)*(\.\w{2,3})+$/;;if (typeof (Page_ClientValidate) == 'function') {Page_ClientValidate("formValidateFeedbackGroup");validForm = validForm && Page_IsValid;}if (validForm) { $("#formWrapper .fieldSubmitButton input[type=submit]").css("display", "none"); $("#formWrapper .fieldSubmitButton .fieldSubmitButtonStatus").css("display", "inline-block"); }return true;}
